Antisense Therapeutics Limited (AU:PER) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Percheron Therapeutics Limited has reported promising preclinical data for avicursen (ATL1102), showing a 66% reduction in seizure frequency in a mouse model of autoimmune epilepsy. This positions avicursen as a potential new treatment option for a condition with limited current therapies, further validating its anti-inflammatory properties. The results also support the drug’s expansion into additional indications beyond Duchenne muscular dystrophy.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.